A phase II, single-arm trial of epratuzumab, an anti-CD22 humanized antibody, in patients with Waldenstrom's macroglobulinaemia
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Epratuzumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Immunomedics
- 05 Feb 2008 Status changed from in progress to dicontinued. Trial terminated due to low accrual.
- 02 Jan 2006 New trial record.